Monkeypox Vaccine and Treatment Market Size & Growth Forecast 2026–2035, By Segments (Route of Administration, Product, Gender, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Monkeypox Vaccine and Treatment Market size was worth USD 109.65 Million in 2025 and is expected to grow at a 10.1% CAGR between 2026 and 2035, reaching USD 287 Million by 2035. The industry revenue for 2026 is assessed at USD 119.52 million.
Get more details on this report
Request Free Sample ReportMonkeypox Vaccine and Treatment Market Intelligence Snapshot
Regional Market Dynamics
- North America captured 42.40% of the market in 2025, supported by strong vaccine procurement systems, advanced healthcare infrastructure, efficient public health response, and established pharmaceutical capabilities.
- Asia Pacific is forecast to grow at an 11.31% CAGR, fueled by stronger disease surveillance, expanding healthcare access, improved outbreak preparedness, and growing vaccine and treatment procurement.
Segment Momentum
- Drugs held a 67.9% share in 2025 because they remain central to managing active infections, supporting routine clinical treatment and patient care during disease outbreaks.
- Vaccines are expanding fastest as disease-control strategies increasingly emphasize prevention, supporting broader immunization efforts and stronger public health preparedness against future outbreaks.
Market Expansion Drivers
- Large-scale government vaccination campaigns accelerating outbreak containment and immunization coverage.
- Emergency use authorizations and accelerated regulatory approvals enabling rapid vaccine deployment.
- Strengthening global disease surveillance and outbreak preparedness programs improving response coordination.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Major companies in the monkeypox vaccine and treatment market include Bavarian Nordic A/S (Denmark), SIGA Technologies, Inc. (United States), Chimerix, Inc. (United States), Emergent BioSolutions Inc. (United States), Gilead Sciences, Inc. (United States), Pfizer Inc. (United States), Moderna, Inc. (United States), Merck & Co., Inc. (United States), BioNTech SE (Germany), Tonix Pharmaceuticals Holding Corp. (United States).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
Large-scale public vaccination efforts convert policy intent into immediate procurement, distribution, and administration activity, creating a direct pathway for demand in the monkeypox vaccine and treatment market. When governments prioritize ring vaccination, high-risk population coverage, and stockpile deployment, manufacturers gain clearer volume visibility while healthcare systems expand cold-chain logistics, clinic capacity, and public-health coordination to move doses quickly. This compresses the time between outbreak detection and immunization, increasing market penetration by turning episodic emergency purchasing into organized, program-led demand and reinforcing the role of approved vaccines and supportive therapeutics in routine outbreak response planning.
Emergency use authorizations and accelerated regulatory approvals enabling rapid vaccine deployment
Emergency use authorizations shorten the commercial and operational gap between product readiness and field use, which is especially important in the monkeypox vaccine and treatment market where outbreak response depends on speed rather than traditional launch timelines. Faster regulatory pathways allow health agencies to begin procurement and distribution earlier, while hospitals, public-health departments, and international buyers gain greater confidence in adopting vaccines and related treatments under defined emergency frameworks. This accelerates market adoption by reducing approval-related delays in contracting, inventory positioning, and clinical deployment, and it also encourages manufacturers to scale production sooner because demand can materialize while outbreaks are still active.
Strengthening global disease surveillance and outbreak preparedness programs improving response coordination
As surveillance systems become more integrated, suspected cases are identified earlier and response triggers become more standardized, driving market development in the monkeypox vaccine and treatment market. Better coordination among laboratories, public-health agencies, and emergency response networks improves the timing of vaccine requests, treatment allocation, and stockpile activation, reducing the fragmentation that often slows outbreak control. Preparedness programs also shape purchasing behavior before crises escalate, as governments and multilateral health bodies formalize response protocols, maintain reserve inventories, and invest in readiness infrastructure that supports more consistent demand for vaccines and therapeutic options.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Large-scale government vaccination campaigns accelerating outbreak containment and immunization coverage | 2.30% | High | North America, Europe | High | Near Term |
| Emergency use authorizations and accelerated regulatory approvals enabling rapid vaccine deployment | 2.00% | High | North America, Europe | High | Near Term |
| Strengthening global disease surveillance and outbreak preparedness programs improving response coordination | 1.60% | High | Global | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held a 42.40% share of the monkeypox vaccine and treatment market in 2025, supported by its established vaccine procurement systems, strong public health response capacity, and broad access to advanced healthcare infrastructure. The region’s leadership is reinforced by the ability of health agencies and care networks to move quickly from case detection to vaccination, treatment access, and stockpile deployment, which keeps commercial and institutional demand concentrated in a well-organized operating environment. Presence of major pharmaceutical and biotechnology activity also supports supply availability, regulatory coordination, and faster integration of approved countermeasures into routine outbreak preparedness frameworks.
Asia Pacific is projected to expand at an 11.31% CAGR over the forecast period in the monkeypox vaccine and treatment market, driven by strengthening disease surveillance, improving healthcare access, and rising government attention to outbreak readiness across densely populated countries. Growth is accelerating as more health systems in the region build practical capacity for vaccine distribution, diagnostic follow-up, and treatment management, creating a broader base for procurement and adoption. Expanding public health infrastructure and increasing responsiveness to emerging infectious disease risks are translating into more active preparedness measures, which is pushing market development faster than in more mature regions.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Coordinated Public Health ResponseGermany is focusing on integrating vaccination and therapeutic access within established infectious disease preparedness frameworks. German authorities continue to support monitoring programs and healthcare provider awareness to strengthen outbreak management capabilities.
France 🇫🇷
Preventive Immunization FocusFrance is maintaining emphasis on preventive vaccination strategies and the availability of therapeutic options for vulnerable groups. The French market is shaped by continued public health planning and efforts to ensure rapid intervention capabilities during case clusters.
Italy 🇮🇹
Healthcare Response CapacityItaly is prioritizing preparedness planning and healthcare coordination to manage potential mpox outbreaks effectively. Italian health authorities are focusing on securing vaccine access and reinforcing clinical protocols for diagnosis, treatment, and patient management.
Japan 🇯🇵
Targeted Containment MeasuresJapan is emphasizing early detection and targeted immunization strategies to limit the spread of mpox cases. The market in Japan is centered on maintaining access to vaccines and treatments while reinforcing preparedness across healthcare institutions.
South Korea 🇰🇷
Surveillance-Led ReadinessSouth Korea is reinforcing disease surveillance and response mechanisms to support timely deployment of vaccines and treatments. Healthcare authorities in South Korea are prioritizing coordinated preparedness measures and strengthening public health communication around mpox risks.
United States 🇺🇸
Preparedness Stockpiling StrategyThe U.S. continues to prioritize vaccine procurement and treatment readiness to support rapid response capabilities during mpox outbreaks. Public health agencies in the U.S. are emphasizing surveillance, strategic reserves, and targeted vaccination programs for at-risk populations.
Segment Leadership and Growth Trends
Monkeypox Vaccine and Treatment Market Share (%), Route of Administration, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportOral administration held a 63.05% share of the monkeypox vaccine and treatment market in 2025, making it the leading route within this segment. Its position is underpinned by practical treatment-use advantages, especially where ease of administration, patient compliance, and broader accessibility matter in real-world care settings. Oral products are often better aligned with routine therapeutic delivery, which helps sustain their leadership in the monkeypox vaccine and treatment market as providers and patients favor formats that are simpler to distribute and use without added procedural requirements.
Injectable administration is emerging as the fastest-growing route in the monkeypox vaccine and treatment market, driven primarily by the expanding role of vaccines in outbreak response and prevention strategies. Compared with oral options, injectables are gaining momentum because they are more closely tied to immunization programs and structured public health deployment, where controlled dosing and organized administration are critical. This route is therefore benefiting from rising attention to preventive intervention, which is accelerating growth relative to alternatives centered more on treatment convenience.
Product Segment Analysis: Drugs (Largest Segment) vs Vaccine (Fastest-Growing Segment)
Within the monkeypox vaccine and treatment market, drugs accounted for a 67.9% share in 2025, establishing them as the largest product segment. This leadership reflects the immediate need to manage active infections and symptoms, which keeps drug-based interventions central to market demand. Their dominant share is sustained by the practical role they play in clinical care, where treatment availability remains essential for addressing confirmed cases and supporting patient management during periods of disease incidence.
Vaccine is the fastest-growing product segment in the monkeypox vaccine and treatment market as prevention becomes a stronger focus in disease-control efforts. Growth is being encouraged by the shift toward proactive containment measures, particularly where reducing transmission risk is more effective than relying only on post-infection treatment. Relative to drugs, vaccines are gaining momentum because they align more directly with public health preparedness and outbreak mitigation requirements, creating stronger expansion potential as preventive coverage receives greater attention.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Route of Administration | Oral, Injectable | Oral | Injectable |
| Product | Vaccine, Drugs, Vaccinia Immune Globulin (VIG) | Drugs | Vaccine |
| Gender | Male, Female, Others | Male | Female |
| End-use | Hospitals, Specialty Clinics, Others | Hospitals | Specialty Clinics |
Competitive Landscape and Market Positioning
1. Bavarian Nordic A/S (Denmark)
2. SIGA Technologies Inc. (United States)
3. Chimerix Inc. (United States)
4. Emergent BioSolutions Inc. (United States)
5. Gilead Sciences Inc. (United States)
6. Pfizer Inc. (United States)
7. Moderna Inc. (United States)
8. Merck & Co. Inc. (United States)
9. BioNTech SE (Germany)
10. Tonix Pharmaceuticals Holding Corp. (United States)
The monkeypox vaccine and treatment market is shaped by accelerated medical research and rapid therapeutic development. R&D investments are focusing on improving vaccine efficacy and treatment responsiveness. Collaborative efforts with health organizations are enabling faster deployment and response readiness. Regulatory pathways are also influencing speed of approval and distribution.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| KM Biologics | Aug-22 | Japan approved KM Biologics’ LC16 KMB vaccine for monkeypox disease, expanding available immunization options for orthopoxvirus infections. The approval strengthens national preparedness and supports broader vaccine deployment strategies for emerging infectious disease control and outbreak response capabilities. |
| KM Biologics | Aug-22 | KM Biologics’ LC16 KMB vaccine received approval in Japan for monkeypox disease, expanding national preparedness and vaccine availability for orthopoxvirus outbreaks. This regulatory approval strengthens the company’s position in infectious disease vaccine supply within the evolving global monkeypox response ecosystem. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Monkeypox Vaccine and Treatment Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Monkeypox Vaccine and Treatment Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchHow much revenue does the monkeypox vaccine and treatment market generate?
How is the monkeypox vaccine and treatment industry size expected to evolve during the forecast period?
How are large-scale vaccination campaigns influencing demand in the monkeypox vaccine and treatment market?
How do emergency use authorizations impact commercialization in this market?
Which product segment led the monkeypox vaccine and treatment market in 2025?
Why are vaccines the fastest-growing product segment in the monkeypox vaccine and treatment market?
Why does North America lead the monkeypox vaccine and treatment market?
What is driving monkeypox vaccine and treatment market growth in Asia Pacific?
What are the prominent companies operating in the monkeypox vaccine and treatment landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization